Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cough medicine
Biotech
GSK axes key cough drug candidate after phase 3 data disappoint
GSK ended development after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as a key catalyst.
Nick Paul Taylor
Jul 17, 2026 5:46am
Exxel plans $13M IPO to score where other FAAH inhibitors failed
Feb 3, 2026 11:33am
Seyltx gains option to boost cough pipeline with 8 NeurOp drugs
Jun 5, 2025 10:40am
Roche culls cough candidate, pivots KRAS program in Q3 update
Oct 23, 2024 6:35am
After $2B acquisition, GSK sends some Bellus workers packing
Mar 22, 2024 11:08am
GSK tips 12 blockbuster launches to soften HIV patent loss
Jan 31, 2024 7:45am
